Jiandie D. Lin

Jiandie D. Lin

Auto-generated profile, based on publicly available information

Jiandie D. Lin

Life Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, Michigan, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2019 in Molecular Cell
Verified
Journal Article
Closed access
XXXuelian Xiong
Xuelian Xiong
HKHenry Kuang
Henry Kuang
SASahar Ansari
Sahar Ansari
TLTongyu Liu
Tongyu Liu
JGJianke Gong
Jianke Gong
JLJiandie D. Lin
Jiandie D. Lin

17 November 2014 in Nature Medicine
Verified
Journal Article
Open access
PDF file
GWGuo-Xiao Wang
Guo-Xiao Wang
XZXu-Yun Zhao
Xu-Yun Zhao
ZMZhuo-Xian Meng
Zhuo-Xian Meng
MKMatthias Kern
Matthias Kern
ADArne Dietrich
Arne Dietrich
JLJiandie D Lin
Jiandie D Lin
The brown fat-derived neuregulin 4 regulates hepatic lipid homeostasis and whole-body insulin sensitivity Brown fat activates uncoupled respiration in response to cold temperature and contributes to systemic metabolic homeostasis. To date, the metabolic action of brown fat has been primarily attributed to its role in fuel oxidation and uncoupling protein 1 (UCP1)-mediated thermogenesis. Whether brown fat engages other tissues through secreted factors remains largely unexplored. Here we show that neuregulin 4 (Nrg4), a member of the epidermal growth factor (EGF) family of extracellular ligands, is highly expressed in adipose tissues, enriched in brown fat and markedly increased during brown adipocyte differentiation. Adipose tissue Nrg4 expression was reduced in rodent and human obesity. Gain- and loss-of-function studies in mice demonstrated that Nrg4 protects against diet-induced insulin resistance and hepatic steatosis through attenuating hepatic lipogenic signaling. Mechanistically, Nrg4 activates ErbB3 and ErbB4 signaling in hepatocytes and negatively regulates de novo lipogenesis mediated by LXR and SREBP1c in a cell-autonomous manner. These results establish Nrg4 as a brown fat–enriched endocrine factor with therapeutic potential for the treatment of obesity-associated disorders, including type 2 diabetes and nonalcoholic fatty liver disease (NAFLD).

1 August 2014 in Molecular Cell
Verified
Journal Article
Closed access
XZXu-Yun Zhao
Xu-Yun Zhao
SLSiming Li
Siming Li
GWGuo-Xiao Wang
Guo-Xiao Wang
QYQi Yu
Qi Yu
JLJiandie D. Lin
Jiandie D. Lin

6 September 2011 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
DMDi Ma
Di Ma
SPSatchidananda Panda
Satchidananda Panda
JLJiandie D Lin
Jiandie D Lin

16 February 2011 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Open access
PDF file
CLChang Liu
Chang Liu
JLJiandie D. Lin
Jiandie D. Lin
Chronic disruption of energy balance, where energy intake exceeds expenditure, is a major risk factor for the development of metabolic syndrome. The latter is characterized by a constellation of symptoms including obesity, dyslipidemia, insulin resistance, hypertension, and non-alcoholic fatty liver disease. Altered expression of genes involved in glucose and lipid metabolism as well as mitochondrial oxidative phosphorylation has been implicated in the pathogenesis of these disorders. The peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1) family of transcriptional coactivators is emerging as a hub linking nutritional and hormonal signals and energy metabolism. PGC-1α and PGC-1β are highly responsive to environmental cues and coordinate metabolic gene programs through interaction with transcription factors and chromatin-remodeling proteins. PGC-1α has been implicated in the pathogenic conditions including obesity, type 2 diabetes, neurodegeneration, and cardiomyopathy, whereas PGC-1β plays an important role in plasma lipoprotein homeostasis and serves as a hepatic target for niacin, a potent hypotriglyceridemic drug. Here, we review recent advances in the identification of physiological and pathophysiological contexts involving PGC-1 coactivators, and also discuss their implications for therapeutic development.

1 May 2015 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
GWGuo-Xiao Wang
Guo-Xiao Wang
XZXu-Yun Zhao
Xu-Yun Zhao
JLJiandie D. Lin
Jiandie D. Lin